Upon joining the study, eligibility is confirmed based on specific criteria, including a diagnosis of Stage III or Stage IV melanoma that has been completely removed through surgery.

A complete physical examination and imaging studies are conducted to ensure the absence of disease.

Participants are randomly assigned to one of two groups: one receiving a combination of nivolumab and relatlimab, and the other receiving nivolumab alone.

This process is double-blind, meaning neither the participants nor the researchers know which treatment is being administered to each participant.

The treatment involves intravenous administration of the medication. Nivolumab is given as a 10 mg/mL concentrate for infusion, while the combination treatment includes nivolumab 240 mg and relatlimab 80 mg per vial.

The frequency and duration of the treatment are determined by the study protocol and are administered under medical supervision.

Participants are regularly monitored for any side effects or adverse reactions to the treatment. This includes routine laboratory tests and assessments by healthcare professionals.

The study aims to measure the time until any recurrence of melanoma or death, as well as overall survival and other health outcomes.

The study is estimated to conclude by November 2029. Participants will continue to be monitored until the study’s end date or until they meet specific criteria for withdrawal from the study.